Androgen deprivation therapy ‘ups all-cause mortality risk’
Men receiving the therapy for prostate cancer are also more likely to experience adverse CV outcomes, researchers say
Patients with prostate cancer given primary androgen deprivation therapy have up to double the risk of major cardiac events and death than men receiving other treatments, a study shows.
Norwegian researchers say the likelihood of adverse outcomes was particularly high in those already at moderate risk of cardiovascular disease (CVD) and those with longer duration of treatment.
